La Merie Publishing is an independent business information provider for the biotechnology and pharmaceutical industry. We publish proprietary reports and prepare custom reports.
The report covers 2023 sales data of innovator therapeutic antibodies and proteins, biosimilars and the novel biologic drug modalities gene & cell therapy and RNA products STUTTGART, Germany I March 08, 2024 I La Merie Publishing released the new report with sales data of recombinant biologics, biosimilars and novel biologic...
BARCELONA, Spain I March 08, 2023 I La Merie Publishing released the 17th edition of its report series about sales of recombinant biologics. The report 2022 Sales of Recombinant Therapeutic Antibodies, Proteins, Biosimilars & Other Biologics provides a compilation of the sales data of originator and biosimilar recombinant therapeutic proteins...
BARCELONA, Spain I February 07, 2023 I La Merie Publishing released today its newest report entitled “CAR-M Industry Landscape Analysis: Chimeric Antigen Receptor-Macrophage (CAR-M) Stakeholders, Technologies, Pipeline, Partnering and Financing”. This report provides a landscape description and analysis of the emerging technology of Chimeric Antigen Receptor Macrophages (CAR-M) from an...
BARCELONA, Spain I November 13, 2022 I La Merie Publishing released today its newest report entitled “RNA-Targeted Novel Drug Modalities Based on RNA Editing, Epitranscriptomics, Direct RNA Targeting, Splicing Modulation, Translation Regulation, lncRNA & regRNA Targeting & More: a landscape analysis of technologies, targets, business and financing from an industry...
BARCELONA, Spain I July 6, 2022 I La Merie Publishing released today a report bundle entitled “Claudin 6, Cadherin 17, ROR1 and GPRC5D-Targeted Therapies: Target Expression Profile, Safety & Efficacy of Drug Modalities, Pipeline Review, and Competitive Landscape Analysis”. This report bundle includes four reports about novel cancer targets which...
BARCELONA, Spain I July 1, 2022 I La Merie Publishing released today its newest report entitled “GPRC5D-Targeted Therapy: Target Expression Profile, Safety & Efficacy of Drug Modalities, Pipeline Review, and Competitive Landscape Analysis”. This report evaluates G-protein–coupled receptor family C group 5 member D (GPRC5D) from an industry perspective for...
BARCELONA, Spain I June17, 2022 I La Merie Publishing released today its newest report entitled “ROR1-Targeted Therapy: Target Expression Profile, Safety & Efficacy of Drug Modalities, Pipeline Review, and Competitive Landscape Analysis”. This report evaluates Receptor tyrosine kinase-like Orphan Receptor 1 (ROR1) from an industry perspective for its suitability as...
BARCELONA, Spain I May 20, 2022 I La Merie Publishing released today its newest report entitled “Cadherin 17: A target opportunity to develop effector-enhanced drug modalities”. This report describes and analyzes cadherin 17 as a target opportunity for development of effector-enhanced drug modalities as of May 2022. Cadherins are a...
BARCELONA, Spain I May 13, 2022 I La Merie Publishing released today its newest report entitled “Claudin 6: A target opportunity to develop effector-enhanced drug modalities”. This report describes and analyzes claudin 6 as a target opportunity for development of effector-enhanced drug modalities as of May 2022. Claudin 6 (CLDN6)...
BARCELONA, Spain I March 16, 2021 I La Merie Publishing released the 16th edition of its annual report about sales of recombinant biologics. The report 2021 Sales of Recombinant Therapeutic Antibodies, Proteins, Biosimilars & Other Biologics provides a compilation of the sales data of originator and biosimilar recombinant therapeutic proteins...
